Skip to content
10-Q

Quarterly Report

BIOFORCE NANOSCIENCES HOLDINGS, INC. BFNH

0001091818-24-000134

← back to feed
Filed
Nov 8, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Nov 7, 2024 29.27M sh
Cash And Equivalents Q3 2024 · Sep 30, 2024 $1.64K
Cash And Equivalents Q3 2024 · Dec 31, 2023 $638
Current Liabilities Q3 2024 · Sep 30, 2024 $2.18M
Current Liabilities Q3 2024 · Dec 31, 2023 $1.82M
Total Liabilities Q3 2024 · Sep 30, 2024 $2.18M
Total Liabilities Q3 2024 · Dec 31, 2023 $1.82M
Current Assets Q3 2024 · Sep 30, 2024 $1.64K
Current Assets Q3 2024 · Dec 31, 2023 $638
Total Assets Q3 2024 · Sep 30, 2024 $1.64K
Total Assets Q3 2024 · Dec 31, 2023 $638
Shares Diluted Q3 2024 · Sep 30, 2023 29.27M sh
Shares Diluted Q3 2024 · Sep 30, 2023 29.27M sh
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$39.62K
Stockholders Equity Q3 2024 · Sep 30, 2023 −$1.7M
Stockholders Equity Q3 2024 · Jun 30, 2023 −$1.59M
Stockholders Equity Q3 2024 · Mar 31, 2023 −$1.48M
Stockholders Equity Q3 2024 · Dec 31, 2022 −$1.35M
Eps Diluted Q3 2024 · Sep 30, 2023 $0.00
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$0.01
Eps Basic Q3 2024 · Sep 30, 2023 $0.00
Eps Basic restated Q3 2024 · Sep 30, 2023 −$0.01
Sga Expense Q3 2024 · Sep 30, 2023 $7.86K
Sga Expense Q3 2024 · Sep 30, 2023 $40.29K
Net Income Q3 2024 · Sep 30, 2023 −$113.61K
Net Income Q3 2024 · Sep 30, 2023 −$357.54K